Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122826 | 0.72 | CHRNA7 (0.36) | OPRM1SLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL16566109 | 0.65 | KDM1A (0.39) | OPRM1KDM1AOPRL1ATM | |
| SCHEMBL1670650 | 0.65 | TNKS (0.46) | OPRM1OPRL1KDM4ESIGMAR1 | |
| SCHEMBL5674186 | 0.65 | KDM1A (0.41) | OPRM1KDM1AOPRL1KDM4EATM | |
| SCHEMBL12791302 | 0.64 | OPRM1 (0.42) | MAPK1OPRM1KDM1AOPRL1KDM4E | |
| SCHEMBL30154972 | 0.64 | MAPK1 (0.38) | MAPK1SMN1; SMN2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL25230408 | 0.64 | TNKS (0.45) | OPRM1OPRL1KDM4ESIGMAR1 | |
| SCHEMBL4270096 | 0.63 | TNKS (0.42) | OPRM1KDM1AOPRL1KDM4ESIGMAR1 | |
| SCHEMBL14426246 | 0.62 | TNKS (0.40) | OPRM1OPRD1OPRK1OPRL1SIGMAR1 | |
| SCHEMBL16566273 | 0.62 | KDM1A (0.36) | OPRM1KDM1AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910157-B | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2014-05-07 | — | — | CN | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| CN-101910157-A | Indole compounds and methods of treating visceral pain | NEURAXON INC | 2010-12-08 | — | — | CN | disclosed |
| EP-2220075-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| WO-2009062319-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | TPH1, NOS1, IDO1 | MAPK1 883/4885SMN1; SMN2 2539/4885OPRM1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.